HealthEquity (HQY)
(Delayed Data from NSDQ)
$83.09 USD
+4.91 (6.28%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $83.11 +0.02 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.09 USD
+4.91 (6.28%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $83.11 +0.02 (0.02%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth F Momentum C VGM
Zacks News
Why Is HealthEquity (HQY) Down 4.3% Since Last Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is HealthEquity Stock a Buy Now Amid Strength in HSAs?
by Zacks Equity Research
HQY's strong quarterly results and solid top-line growth raise optimism about the stock.
Looking for a Growth Stock? 3 Reasons Why HealthEquity (HQY) is a Solid Choice
by Zacks Equity Research
HealthEquity (HQY) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts Think HealthEquity (HQY) Could Surge 32.88%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for HealthEquity (HQY) points to a 32.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Zacks.com featured highlights include TAL Education, The RealReal, DarioHealth, HealthEquity and Energous
by Zacks Equity Research
TAL Education, The RealReal, DarioHealth, HealthEquity and Energous have been highlighted in this Screen of The Week article.
Bet on 5 Top-Ranked Stocks With Rising P/E for Stellar Gains
by Sanghamitra Saha
Tap five stocks with increasing P/E ratios. These stocks include TAL Education Group (TAL), The RealReal (REAL), DarioHealth (DRIO), HealthEquity (HQY) and Energous (WATT).
Cigna's Health Benefits Unit Launches a New E-Treatment Option
by Zacks Equity Research
CI's new launch, a new E-Treatment option, is expected to improve patient satisfaction and operational efficiency.
Why HealthEquity (HQY) is a Top Momentum Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HQY vs. MEDP: Which Stock Is the Better Value Option?
by Zacks Equity Research
HQY vs. MEDP: Which Stock Is the Better Value Option?
3 Reasons Why Growth Investors Shouldn't Overlook HealthEquity (HQY)
by Zacks Equity Research
HealthEquity (HQY) could produce exceptional returns because of its solid growth attributes.
Wall Street Analysts Believe HealthEquity (HQY) Could Rally 36.59%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 36.6% in HealthEquity (HQY). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
HealthEquity Stock May Gain From Its Latest Partnership With Paytient
by Zacks Equity Research
HQY collaborates with Paytient to enhance employees' access to healthcare through Health Payment Accounts.
HealthEquity Stock Rises on Q2 Earnings and Revenue Beat
by Zacks Equity Research
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
HealthEquity (HQY) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for HealthEquity (HQY) give a sense of how the business performed in the quarter ended July 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
HealthEquity (HQY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 22.86% and 5.43%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
The Cooper Companies (COO) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
The Cooper Companies (COO) delivered earnings and revenue surprises of 5.49% and 0.57%, respectively, for the quarter ended July 2024. Do the numbers hold clues to what lies ahead for the stock?
What Analyst Projections for Key Metrics Reveal About HealthEquity (HQY) Q2 Earnings
by Zacks Equity Research
Evaluate the expected performance of HealthEquity (HQY) for the quarter ended July 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
Here's Why HealthEquity (HQY) is a Strong Growth Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
IceCure Medical (ICCM) delivered earnings and revenue surprises of 14.29% and 12.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Embecta Corp. (EMBC) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Embecta Corp. (EMBC) delivered earnings and revenue surprises of 54.17% and 0.74%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Natera (NTRA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Natera (NTRA) delivered earnings and revenue surprises of 56.52% and 21.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?